Abemaciclib is an experimental therapy being developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.
| SparkCures ID | 325 |
|---|---|
| Developed By | Eli Lilly and Company |
| Brand Name | Verzenio® |
| Generic Name | Abemaciclib |
| Treatment Classifications | |
| Treatment Targets |
|
There are no resources, links or videos to display for this treatment.